BRAF inhibitors are the first targeted therapeutic agents for patients with MM [48], and currently the most representative BRAF inhibitors are Vemurafenib [62], Dabrafenib [63], and Encorafenib [64]. Here, BRAF is linked to Miyoshi myopathy.